500 Boylston Street, Boston, MA 02116 617-419-4700
Return to Results
The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs)
following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.
Ages:18 and older
Inclusion Criteria: - subjects must be at least 18 years of age - subjects with advanced prostate cancer who will receive sipuleucel-T or who underwent their first leukapheresis for manufacture of sipuleucel-T ≤ 6 months prior to enrollment - subjects must understand and sign an informed consent form Exclusion Criteria: - none
Trial ID: NCT01306890
Not Accepting Healthy Volunteers